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Context: The purpose of this study was to conduct a quality improvement (QI), applied 
  practical review of the American Joint Committee on Cancer (AJCC) 7th edition, Carcinoma 
of the Eyelid staging system. AJCC utilizes a primary tumor, lymph node, metastasis (pTNM) 
cancer staging approach.
Objective: We wanted to determine if the AJCC pTNM carcinoma staging system identified 
patients with highly aggressive carcinoma of the eyelid. We also wanted to determine if there 
were any unexpected issues in its practical application. 
Design: We conducted a 15-year, consecutive, retrospective review of all cases of excisional 
biopsy for carcinoma of the eyelid. We reviewed the original histopathology slides and complete 
pathology records for each case.
Results: Over a 15-year review period, 52 cases of excisional biopsy for carcinoma of the 
eyelid were identified. The average age of the study population was 72 years. Nodular well-
differentiated basal cell carcinoma (BCC) was the predominant histology for 85% of cases. 
Morpheaform/metatypical BCC was the next dominant at 9%. Squamous cell carcinoma and 
sebaceous carcinoma followed at 4% and 2%, respectively. We were able to assign clear stag-
ing to 50 of the 52 cases with the available pathology data. The stage results were as follows: 
stage 1A 72%, stage 1B 22%, stage II 4%, stage III 2%, with no cases of stage IV metastatic 
disease.
Conclusions: The 7th edition AJCC Carcinoma of the Eyelid chapter proved to be a   practical 
tool for carcinoma staging of the eyelid. The largest tumor dimension remains an effective 
predictive factor. High-grade pathologic prognostic factors such as tumor necrosis or perineural 
spread had a 100% association with a final stage of II or greater. Concordance and compliance 
was 100% for the recommended site-specific pathologic risk factors. Regarding squamous cell 
carcinoma of the eyelid, three new required data points had a 0% reporting rate over 15 years. 
Overall, smaller less invasive tumors were classified as stage 1A and 1B tumors. More invasive 
and higher risk tumors fell into appropriate higher staging classifications. The newly recom-
mended prognostic site-specific tumor factors appear to work well with a high concordance 
with staging severity, and strong medical community acceptance.
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Introduction
The purpose of this study was to conduct a quality improvement (QI), applied practical 
review of the American Joint Committee on Cancer (AJCC) 7th edition, carcinoma 
of the eyelid staging system. AJCC utilizes a primary tumor, lymph node, metastasis 
(pTNM) cancer staging approach.1 This QI study was not sponsored by the AJCC. 





patients with highly aggressive carcinoma of the eyelid. We 
also wanted to determine if there were any unexpected issues 
in its practical application. In short, does it work, are there 
glitches, and is it effective? In a quality improvement process, 
results are not just data. Results give us better   understanding 
of the tools we use every day, and the potential for their 
improvement in the future.
Cancer staging systems have an inherent tension, 
a dynamic balance between pathologic features and clinical 
staging.2 Questions arise out of this tension and balance. In 
our case, do medial canthal tumors require a distinct prog-
nostic factor status? Does this staging system work for its 
intended target audience? We tested these issues through a 
quality improvement approach. We applied the current cancer 
staging system to a consecutive group of eyelid carcinoma 
cases over a 15-year time span. This time span began on 
January 1, 1990 and ended on January 1, 2005.
Similar tensions between pathologic findings and clinical 
evaluation have arisen in a number of areas in oncology and 
cancer staging.1–14 McLean et al published a multivariate 
analysis regarding ciliary body location of uveal melanoma.3 
Numerous clinical studies showed an increased metastatic 
risk with clinically diagnosed ciliary body melanoma. Ciliary 
body tumors in the AFIP database had a worse prognosis. 
When compared to pathologic features including largest 
tumor dimension and tumor cell type in a multivariate analy-
sis, the results were the same. Instead of disproving one camp 
or another, it showed that the data could be used equally from 
different perspectives.4–14 This is a very similar concept to 
our clinical question of medial canthal tumors.
Methods and materials
We conducted a 15-year, consecutive, retrospective review 
of all cases of excisional biopsy for carcinoma of the eyelid. 
We reviewed the original histopathology slides and pathology 
records for each case. Our pathology working draft docu-
ment contains the gross description of a current case and all 
pathology specimens dating back to January 1, 1990. Thus 
for each case we obtained the original excisional glass slides, 
a pathology working draft, and the pathology final diagnosis 
sheet for staging review. Data collection was limited to stag-
ing data available in the original documents and description 
only. We verified the data but did not collate new features.
In order to facilitate clinical investigations approval, we 
limited our data collection to reduce exposure to protected 
patient health information. Very early in the study we were 
able to redact any information such as name, race, date of 
birth, or any similar identifying information. Data points 
collected did include: age, surgical number, largest tumor 
dimension, derived stage with a pTNM current classification, 
histology, grade, prognostic factors, and required factors as 
listed in the 7th edition Carcinoma of the Eyelid chapter. 
We also obtained location with specific awareness of medial 
and lateral canthus, and the total number of skin and visceral 
carcinomas.
We approached the study as a quality improvement effort. 
As such there was internal and external review to limit such 
factors as selection bias or predetermined findings.
Results
Over a 15-year review period, 52 cases of excisional biopsy 
for carcinoma of the eyelid were identified. The average 
age of the study population was 72 years. Nodular well-
differentiated basal cell carcinoma (BCC) was the predomi-
nant histology for 85% of cases. Morpheaform/metatypical 
BCC was the next most dominant at 9%. Squamous cell 
carcinoma and sebaceous carcinoma followed at 4% and 
2%, respectively.
We were able to assign clear staging to 50 of the 52 cases 
with the available pathology data. Two cases, referred to 
Mohs surgery, did not have a recorded pathology database 
for complete staging. For the remaining 50 cases, the stage 
results were as follows: stage 1A 72%, stage 1B 22%, 
stage II 4%, stage III 2%, with no cases of stage IV metastatic 
disease.
Medial and lateral canthal tumors represented 18% of 
the cases. The staging distribution was very similar to the 
overall study distribution.
High-risk prognostic factors including tumor necrosis, 
perineural spread, pagetoid spread, and multiple carcinoma 
syndromes such as Muir–Torre syndrome, had an 80% 
association with tumors staged at 1B and higher, and a 100% 
association with all tumors greater than or equal to stage II. 
The high-risk prognostic factors recorded in original pathol-
ogy reports were present on QI review, with 100% compliance 
and concordance. This was confirmed by two pathologists 
looking at the original glass slides in quality assurance and 
our subsequent QI review.
Prognostic features fall into two categories in the 7th 
edition chapter on eyelid carcinoma staging, recommended 
and required.4 Prognostic factors (site specific factors) are 
designated as recommended for collection. They include 
pathologic features such as tumor necrosis, or pagetoid spread, 
and clinical features such as a history of HIV or multiple car-
cinoma syndromes. Of the prognostic factors recommended 




Carcinoma of the eyelid
for staging were identified in the recorded pathologic report, 
and concordant with the findings of this study.
In the 7th edition, squamous cell carcinoma of the eyelid 
is the only subset, with more stringent prognostic dataset 
designated as “required for staging”.1 In this subset the data 
compliance in the original report was highly disparate. Some 
features such as grade and presence or absence of perineural 
invasion had a 100% reporting concordance. Other features, 
such as Clark’s level, tumor thickness in mm, and a statement 
that the tissue was not derived from the ear or non-hairy lip 
had 0% reporting. Staging for these two cases of squamous 
cell carcinoma was based on the 6th edition criteria.
The average primary tumor dimension was 3.75 mm. The 
average number of pathologically confirmed skin carcinomas 
and visceral carcinomas was 2.4% and 0.3% per patient, 
respectively. The retrospective review of all pathologic tis-
sues on file dated back to January of 1990 for all patients 
and specimens.
Discussion
All clinicians and pathologists can relate to the importance of 
communication. The tissue submission form for pathologic 
diagnosis requires all vital data. The communication process 
must be clear, concise, and simple to maximize the number 
of teams that can use the data. pTNM classification is a com-
mon language that can assist this process.1,5,7–13 The level of 
assistance is dependent upon an understanding of the limits 
and applications that can be highlighted by such a review.
The AJCC 7th edition Carcinoma of the Eyelid chapter 
was found to be an effective tool for identifying patients with 
aggressive tumors.1 As authors, the following questions came 
to light while conducting this QI exercise:
•	 Do medial canthal tumors represent a unique subset 
worthy of a prognostic value designation?
•	 What measurement is utilized to determine largest tumor 
dimension (LTD)?
•	 Does the objective in grossing eyelid carcinoma for 
margins, change the measurement of LTD?
•	 What were the recurrent carcinoma rates at the same 
site?
•	 What do we do with Mohs specimens?
•	 Why is there such a high noncompliance rate for the newly 
required data section under squamous cell carcinoma of 
the eyelid?
Do medial canthal tumors represent a unique subset of 
carcinomas of the eyelid? A number of studies have identi-
fied this location as an independent clinical risk factor. Our 
numbers were too small to answer this question and our 
patient population may have more access to care, avoiding 
tumors that invade into deeper tissue planes.
High-grade pathologic prognostic factors had a much 
higher association and direct association with higher staging 
values. These two features may be complementary rather 
than in competition. The fact that medial canthal tumors 
were strongly represented in the submitted data indicates the 
surgeons consider this a factor and supply the data in current 
collection formats.
We utilized recorded data for largest tumor dimension 
only based upon pathologically written documents and the 
original glass slides. If the measurement was not recorded as 
part of the gross, or provided as clinical data by the surgeon, 
we utilized measurement from the glass slides. This is a real-
world limitation that is similar to what a tumor registrar may 
face. Unlike whole eyes with solid tumors such as choroidal 
melanoma, the eyelid contracts as soon as it is resected off 
the patient.
Our average largest tumor dimension was 3.75 mm. This 
was measured by glass slide in 100% of cases. As the princi-
pal submitting surgeon, I consider this to be approximately 
50% smaller than expected. There are a number of reasons for 
this disparity. Ensuring surgical margins are free of tumors is 
a principal objective for the pathologist in grossing an eyelid 
carcinoma specimen.1,6 This objective alters the pathologic 
incisions used to sample the tissue. Unlike choroidal mela-
noma, defining the largest tumor dimension may not be the 
primary consideration for sectioning.3 This does not mean 
that pTNM systems don’t work for adnexal tissues of the eye, 
it is just a reality check on how data is obtained and may be 
available to a tumor registrar.
We had a 4% tumor recurrence rate. One case was from 
the 50 cases that underwent oculoplastics approach resection. 
One case was from a total of two Mohs surgical resections. 
Because two cases referred to Mohs surgery did not have 
necessary pathology data, it may be preferable to stage car-
cinomas prior to performing Mohs surgery.
The prognostic features adapted in the 7th edition under 
“recommend risk factors” appear to have a high acceptance 
within our military hospital setting.1 The reporting rate was 
100%. Our pathologists have trained in a variety of der-
matopathology, surgical pathology, general pathology, and 
ophthalmic pathology institutions. This QI study spanned 
the reporting habits of a diverse group of pathologists over 
15 years. They are all associated with the same military 
system.
The compliance rate for the squamous cell carcinoma of 
the eyelid, requiring prognostic features, was widely varied. Clinical Ophthalmology
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There was 100% reporting for such features as tumor grade or 
pathologic risk factors such as perineural spread. However, 
the newest required features – Clark’s level, tumor thick-
ness in mm, and statement that the tissue was not derived 
from the ear or non-hairy lip – had 0% compliance. No 
final pathologic diagnostic reports listed a Clark’s level for 
eyelid SCC. No reports listed tumor thickness in mm, and 
no reports included a statement that the tumor did not come 
from the ear or non-hairy lip. These are all required fields in 
the 7th edition.1 It appears the groundwork for introducing 
such items did not gain sufficient general or dermatopathol-
ogy support to begin its approach as a “required” field. The 
newly required site-specific factors have features that may 
result in a low reporting value within the general pathology 
community.1,2,6
Overall, the 7th edition AJCC Carcinoma of the Eyelid 
chapter proved to be a practical tool for carcinoma staging 
of the eyelid. We learned there may be disparate findings on 
largest tumor dimension. Yet largest tumor dimension remains 
an effective predictive factor particularly as it is supported 
by the remainder of the 7th edition staging features. Smaller 
less invasive tumors were classified as stage 1A and 1B 
tumors. Much more invasive and higher risk tumors fell into 
appropriate higher staging classifications. Our pathologist 
had no difficulty understanding T4 in its current definition. 
However it may be clearer to define T4 as a radical excision 
with positive margins. The newly recommended prognostic 
site-specific tumor factors appear to work well with a high 
concordance with staging severity and strong medical com-
munity acceptance.
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